Jazz scores front-line gastric cancer nod from FDA for ‘practice-changing’ Ziihera

Gastroesophageal adenocarcinoma presents the biggest market opportunity for Jazz Pharmaceuticals’ Ziihera, according to Truist Securities, which forecasts peak sales of the drug to reach $2.5 billion.